In Parkinson disease (PD), pathological processes and neurodegeneration begin long
before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal …

Importance Imaging biomarkers in Parkinson disease (PD) are increasingly important for
monitoring progression in clinical trials and also have the potential to improve clinical care …

The Parkinson's Progression Markers Initiative (PPMI) has collected more than a decade's
worth of longitudinal and multi-modal data from patients, healthy controls, and at-risk …

White matter hyperintensities (WMHs) are commonly assumed to represent non-specific
cerebrovascular disease comorbid to neurodegenerative processes, rather than playing a …

The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …

Brain atrophy has been reported in the early stages of Parkinson's disease, but there have
been few longitudinal studies. How intrinsic properties of the brain, such as anatomical …

Heterogeneity in Parkinson's disease (PD) presents a barrier to understanding disease
mechanisms and developing new treatments. This challenge may be partially overcome by …

Introduction Previous studies have found associations between grey matter atrophy and
white matter hyperintensities (WMH) of vascular origin with cognitive and motor deficits in …

Background: Biochemical and clinical biomarkers correlate with progression rate and
disease severity in Parkinson's disease (PD) but are not sufficiently studied in late PD …

Identification of individuals at high risk for rapid progression of motor and cognitive signs in
Parkinson disease (PD) is clinically significant. Postural instability and gait dysfunction …